|
Gene: CREB3L2 |
Gene summary for CREB3L2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CREB3L2 | Gene ID | 64764 |
Gene name | cAMP responsive element binding protein 3 like 2 | |
Gene Alias | BBF2H7 | |
Cytomap | 7q33 | |
Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | Q70SY1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64764 | CREB3L2 | LZE4T | Human | Esophagus | ESCC | 1.63e-06 | 1.47e-01 | 0.0811 |
64764 | CREB3L2 | LZE20T | Human | Esophagus | ESCC | 1.02e-03 | 8.32e-02 | 0.0662 |
64764 | CREB3L2 | LZE24T | Human | Esophagus | ESCC | 2.21e-07 | 4.97e-02 | 0.0596 |
64764 | CREB3L2 | P1T-E | Human | Esophagus | ESCC | 1.48e-02 | 4.41e-01 | 0.0875 |
64764 | CREB3L2 | P2T-E | Human | Esophagus | ESCC | 1.12e-06 | 9.49e-02 | 0.1177 |
64764 | CREB3L2 | P4T-E | Human | Esophagus | ESCC | 2.96e-24 | 3.07e-01 | 0.1323 |
64764 | CREB3L2 | P5T-E | Human | Esophagus | ESCC | 7.77e-15 | 1.44e-01 | 0.1327 |
64764 | CREB3L2 | P8T-E | Human | Esophagus | ESCC | 7.58e-11 | 3.54e-01 | 0.0889 |
64764 | CREB3L2 | P9T-E | Human | Esophagus | ESCC | 4.48e-09 | 9.44e-02 | 0.1131 |
64764 | CREB3L2 | P10T-E | Human | Esophagus | ESCC | 1.10e-12 | 2.11e-01 | 0.116 |
64764 | CREB3L2 | P11T-E | Human | Esophagus | ESCC | 3.35e-11 | 5.27e-01 | 0.1426 |
64764 | CREB3L2 | P12T-E | Human | Esophagus | ESCC | 1.26e-28 | 5.93e-01 | 0.1122 |
64764 | CREB3L2 | P15T-E | Human | Esophagus | ESCC | 6.06e-17 | 2.47e-01 | 0.1149 |
64764 | CREB3L2 | P16T-E | Human | Esophagus | ESCC | 1.26e-09 | 1.35e-01 | 0.1153 |
64764 | CREB3L2 | P19T-E | Human | Esophagus | ESCC | 1.65e-10 | 7.21e-01 | 0.1662 |
64764 | CREB3L2 | P20T-E | Human | Esophagus | ESCC | 2.19e-02 | 1.32e-02 | 0.1124 |
64764 | CREB3L2 | P21T-E | Human | Esophagus | ESCC | 1.95e-11 | 2.20e-01 | 0.1617 |
64764 | CREB3L2 | P22T-E | Human | Esophagus | ESCC | 3.34e-14 | 1.92e-01 | 0.1236 |
64764 | CREB3L2 | P23T-E | Human | Esophagus | ESCC | 3.71e-10 | 3.42e-01 | 0.108 |
64764 | CREB3L2 | P24T-E | Human | Esophagus | ESCC | 5.46e-09 | 1.50e-01 | 0.1287 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004819318 | Esophagus | ESCC | Golgi vesicle transport | 231/8552 | 296/18723 | 1.82e-30 | 9.63e-28 | 231 |
GO:0034976111 | Esophagus | ESCC | response to endoplasmic reticulum stress | 192/8552 | 256/18723 | 7.15e-22 | 1.30e-19 | 192 |
GO:0035966111 | Esophagus | ESCC | response to topologically incorrect protein | 125/8552 | 159/18723 | 1.44e-17 | 1.27e-15 | 125 |
GO:0006986111 | Esophagus | ESCC | response to unfolded protein | 107/8552 | 137/18723 | 7.01e-15 | 3.87e-13 | 107 |
GO:000688815 | Esophagus | ESCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 102/8552 | 130/18723 | 1.73e-14 | 9.22e-13 | 102 |
GO:0035967111 | Esophagus | ESCC | cellular response to topologically incorrect protein | 90/8552 | 116/18723 | 1.94e-12 | 8.11e-11 | 90 |
GO:0034620111 | Esophagus | ESCC | cellular response to unfolded protein | 74/8552 | 96/18723 | 3.10e-10 | 8.66e-09 | 74 |
GO:003096818 | Esophagus | ESCC | endoplasmic reticulum unfolded protein response | 59/8552 | 74/18723 | 1.90e-09 | 4.36e-08 | 59 |
GO:003134616 | Esophagus | ESCC | positive regulation of cell projection organization | 201/8552 | 353/18723 | 1.19e-05 | 1.11e-04 | 201 |
GO:001097516 | Esophagus | ESCC | regulation of neuron projection development | 240/8552 | 445/18723 | 2.48e-04 | 1.53e-03 | 240 |
GO:00109764 | Esophagus | ESCC | positive regulation of neuron projection development | 91/8552 | 163/18723 | 5.72e-03 | 2.13e-02 | 91 |
GO:00512161 | Esophagus | ESCC | cartilage development | 103/8552 | 190/18723 | 1.08e-02 | 3.67e-02 | 103 |
GO:00020623 | Esophagus | ESCC | chondrocyte differentiation | 60/8552 | 106/18723 | 1.53e-02 | 4.94e-02 | 60 |
GO:004819321 | Liver | HCC | Golgi vesicle transport | 217/7958 | 296/18723 | 2.58e-27 | 1.02e-24 | 217 |
GO:003497612 | Liver | HCC | response to endoplasmic reticulum stress | 189/7958 | 256/18723 | 1.43e-24 | 4.06e-22 | 189 |
GO:003596612 | Liver | HCC | response to topologically incorrect protein | 123/7958 | 159/18723 | 2.60e-19 | 3.44e-17 | 123 |
GO:000688821 | Liver | HCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 100/7958 | 130/18723 | 1.15e-15 | 8.67e-14 | 100 |
GO:000698612 | Liver | HCC | response to unfolded protein | 103/7958 | 137/18723 | 6.50e-15 | 4.48e-13 | 103 |
GO:003596712 | Liver | HCC | cellular response to topologically incorrect protein | 89/7958 | 116/18723 | 5.61e-14 | 3.39e-12 | 89 |
GO:003462012 | Liver | HCC | cellular response to unfolded protein | 71/7958 | 96/18723 | 3.70e-10 | 1.22e-08 | 71 |
Page: 1 2 3 4 5 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516622 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
hsa0421121 | Liver | HCC | Longevity regulating pathway | 61/4020 | 89/8465 | 4.46e-05 | 2.37e-04 | 1.32e-04 | 61 |
hsa0415241 | Liver | HCC | AMPK signaling pathway | 77/4020 | 121/8465 | 2.32e-04 | 1.11e-03 | 6.18e-04 | 77 |
hsa046684 | Liver | HCC | TNF signaling pathway | 73/4020 | 114/8465 | 2.53e-04 | 1.19e-03 | 6.63e-04 | 73 |
hsa051652 | Liver | HCC | Human papillomavirus infection | 188/4020 | 331/8465 | 3.34e-04 | 1.49e-03 | 8.29e-04 | 188 |
hsa0516322 | Liver | HCC | Human cytomegalovirus infection | 131/4020 | 225/8465 | 6.86e-04 | 2.77e-03 | 1.54e-03 | 131 |
hsa052032 | Liver | HCC | Viral carcinogenesis | 117/4020 | 204/8465 | 2.68e-03 | 8.98e-03 | 5.00e-03 | 117 |
hsa049624 | Liver | HCC | Vasopressin-regulated water reabsorption | 30/4020 | 44/8465 | 4.41e-03 | 1.32e-02 | 7.34e-03 | 30 |
hsa0492241 | Liver | HCC | Glucagon signaling pathway | 64/4020 | 107/8465 | 6.70e-03 | 1.87e-02 | 1.04e-02 | 64 |
hsa049262 | Liver | HCC | Relaxin signaling pathway | 75/4020 | 129/8465 | 9.33e-03 | 2.46e-02 | 1.37e-02 | 75 |
hsa051612 | Liver | HCC | Hepatitis B | 91/4020 | 162/8465 | 1.56e-02 | 3.76e-02 | 2.09e-02 | 91 |
hsa0501632 | Liver | HCC | Huntington disease | 219/4020 | 306/8465 | 3.06e-18 | 3.42e-16 | 1.90e-16 | 219 |
hsa0502032 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0471432 | Liver | HCC | Thermogenesis | 170/4020 | 232/8465 | 5.36e-16 | 2.25e-14 | 1.25e-14 | 170 |
hsa0493131 | Liver | HCC | Insulin resistance | 77/4020 | 108/8465 | 3.89e-07 | 4.46e-06 | 2.48e-06 | 77 |
hsa0516632 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
hsa0421131 | Liver | HCC | Longevity regulating pathway | 61/4020 | 89/8465 | 4.46e-05 | 2.37e-04 | 1.32e-04 | 61 |
hsa0415251 | Liver | HCC | AMPK signaling pathway | 77/4020 | 121/8465 | 2.32e-04 | 1.11e-03 | 6.18e-04 | 77 |
hsa0466811 | Liver | HCC | TNF signaling pathway | 73/4020 | 114/8465 | 2.53e-04 | 1.19e-03 | 6.63e-04 | 73 |
hsa051653 | Liver | HCC | Human papillomavirus infection | 188/4020 | 331/8465 | 3.34e-04 | 1.49e-03 | 8.29e-04 | 188 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CREB3L2 | SNV | Missense_Mutation | c.375C>G | p.Ile125Met | p.I125M | Q70SY1 | protein_coding | tolerated(0.11) | possibly_damaging(0.797) | TCGA-BH-A0C0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
CREB3L2 | SNV | Missense_Mutation | rs754799812 | c.269G>A | p.Arg90Gln | p.R90Q | Q70SY1 | protein_coding | tolerated(0.05) | benign(0.183) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CREB3L2 | SNV | Missense_Mutation | c.1315N>A | p.Glu439Lys | p.E439K | Q70SY1 | protein_coding | deleterious(0.01) | possibly_damaging(0.907) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
CREB3L2 | SNV | Missense_Mutation | rs778038461 | c.419C>T | p.Pro140Leu | p.P140L | Q70SY1 | protein_coding | tolerated(0.1) | probably_damaging(0.998) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CREB3L2 | SNV | Missense_Mutation | c.1455N>T | p.Glu485Asp | p.E485D | Q70SY1 | protein_coding | tolerated(0.17) | benign(0.164) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
CREB3L2 | SNV | Missense_Mutation | c.1418T>C | p.Leu473Pro | p.L473P | Q70SY1 | protein_coding | tolerated(0.28) | possibly_damaging(0.491) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CREB3L2 | SNV | Missense_Mutation | novel | c.938G>T | p.Arg313Ile | p.R313I | Q70SY1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CREB3L2 | insertion | Nonsense_Mutation | novel | c.1441_1442insTATTTGAGAATTTGGCTACTTGCTGATATTTATTTGTCACCCTA | p.Glu481ValfsTer9 | p.E481Vfs*9 | Q70SY1 | protein_coding | TCGA-F5-6465-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
CREB3L2 | SNV | Missense_Mutation | c.1455G>T | p.Glu485Asp | p.E485D | Q70SY1 | protein_coding | tolerated(0.17) | benign(0.164) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
CREB3L2 | SNV | Missense_Mutation | novel | c.958G>A | p.Asp320Asn | p.D320N | Q70SY1 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |